



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

September 17, 2013

Via E-Mail

Robert W. Peabody
Chief Financial Officer
Asterias Biotherapeutics, Inc.
1301 Harbor Bay Parkway, Suite 100
Alameda, California 94

**Re: Asterias Biotherapeutics, Inc.
Amendment No. 3 to Registration Statement on Form S-1
Filed September 3, 2013
Response dated September 12, 2013
File No. 333-187706**

Dear Mr. Peabody:

We have reviewed your supplemental response dated September 12, 2013 to our comment letter issued September 11, 2013 and have the following comments.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Summary Financial Data, page 11

1. You indicate that a valuation of the non-cash assets has not been performed and will be made after completion of the Asset Contribution Agreement. Please expand your disclosure in Note 5 to explain the uncertainties, underlying your estimated value of \$31,271,346 for "intangible assets as a group," and the expected impact on your future operating results and financial condition, if the valuation performed does not support the \$31,271,346 value attributed to these intangible assets.

Risk Factors

Risks Related to Our Business Operations, page 11

2. You state that the choice and prioritization of products from the Contributed Geron Assets are not presently determinable and that the condition of these cells, cell lines and

other biological materials cannot be evaluated prior to completion of the Asset Contribution Agreement. Please provide a separate risk factor that clearly highlights the uncertainties regarding your initial valuation of \$31,271,346 for the contributed Geron and BioTime assets and discusses the risk that the ultimate valuation of these assets could be substantially different from the value presented.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Act of 1933 and all applicable Securities Act rules require. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

Notwithstanding our comments, in the event you request acceleration of the effective date of the pending registration statement please provide a written statement from the company acknowledging that:

- should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
- the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
- the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Please refer to Rules 460 and 461 regarding requests for acceleration. We will consider a written request for acceleration of the effective date of the registration statement as confirmation of the fact that those requesting acceleration are aware of their respective responsibilities under the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed public offering of the securities specified in the above registration statement. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.

Robert W. Peabody
Asterias Biotherapeutics, Inc.
September 17, 2013
Page 3

You may contact Franklin Wyman at (202) 551-3660 or Mary Mast at (202) 551-3613 if you have questions regarding comments on the financial statements and related matters. Please contact Amy Reischauer at (202) 551-3793, Bryan Pitko at (202) 551-3203, or me at (202) 551-3715 with any other questions.

Sincerely,

/s/ Bryan J. Pitko for

Jeffrey P. Riedler
Assistant Director

cc: Via E-Mail
Richard S. Soroko
Thompson, Welch, Soroko & Gilbert LLP
235 Pine Street, 13th Floor
San Francisco, California 94104